Drug intelligence / Profile preview

Rhod-ben

Development stage: Preclinical
Modality: Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Unknown; Likely Intravenous Or Local Administration Followed By Targeted Illumination.

Overview

Rhod-ben is a light-activated drug delivery system designed to release the anticancer agent bendamustine specifically in targeted cells. Under green light (wavelength approximately 550 nm), the carbon-oxygen bond in the compound is broken, resulting in the release of bendamustine. This approach allows for spatial and temporal control of drug activation, potentially reducing off-target toxicity and improving efficacy, particularly for applications such as breast cancer therapy[1].

Brand names: Rhod-ben
Other names: Rhod-ben

Targets

DNA

Beyond the preview

Go deeper on Rhod-ben.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rhod-ben.

Explore the full profile